Trevi Therapeutics Inc (OQ:TRVI)

May 07, 2020 04:05 pm ET
Trevi Therapeutics Announces First Quarter 2020 Financial Results and Corporate Update
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
Apr 08, 2020 04:05 pm ET
TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present...
Mar 16, 2020 08:00 am ET
TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
Feb 20, 2020 04:05 pm ET
Trevi Therapeutics to Present at SVB Leerink Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present...
Feb 18, 2020 04:05 pm ET
Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors
Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella,...
Nov 14, 2019 04:05 pm ET
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
Nov 13, 2019 05:01 pm ET
Trevi Therapeutics to Present at Stifel Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present...
Sep 05, 2019 04:05 pm ET
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Jennifer L. Good,...
Aug 12, 2019 04:05 pm ET
Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
Jun 18, 2019 04:05 pm ET
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Company management will...
Jun 13, 2019 04:09 pm ET
Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
May 07, 2019 01:22 pm ET
Trevi Therapeutics Announces Pricing of Initial Public Offering
Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public...